Sanofi's Cerdelga Receives Continued EMA Approval in Europe and Expanded Indication for Pediatric Use in Gaucher Disease
Cerdelga's Successful Approval Maintained in the European Market
The European Medicines Agency (EMA) has reaffirmed the marketing authorization for Cerdelga (eliglustat), an oral treatment for Gaucher disease. Developed by Sanofi, Cerdelga has undergone rigorous post-approval reviews since its initial European approval in 2015, culminating in the 22nd revision. This demonstrates its recognition as a substrate reduction therapy (SRT) with long-term safety and efficacy. Cerdelga offers convenient oral administration and has become a key treatment that has transformed the treatment paradigm for Gaucher disease.
Differentiated Market Value of Substrate Reduction Therapy (SRT)
Cerdelga is a glucosylceramide synthase (GCS) inhibitor that inhibits the synthesis of glucosylceramide, the causative agent of type 1 Gaucher disease. Existing enzyme replacement therapy (ERT) requires periodic intravenous infusions, whereas Cerdelga is an oral medication taken once or twice daily, significantly improving the quality of life for patients. It has demonstrated superior tolerability and efficacy compared to first-generation SRT drugs such as miglustat, solidifying its leading market position. This clinical value is a key asset that supports Sanofi's dominance in the global rare disease market.
Expanding Treatment Options with Expanded Pediatric Indication
The European Medicines Agency (CHMP) has recommended expanding the indication for Cerdelga to include children aged 6 years and older (weighing 15 kg or more) with Gaucher disease whose symptoms are stabilized with ERT. This is a significant milestone that will help young patients avoid the pain of injections and maintain their daily lives. The expanded pediatric indication will facilitate the entry of new patients and create opportunities to maximize synergy with existing Gaucher disease treatments such as Cerezyme. It will serve as a regulatory breakthrough that widens the gap with competing drugs.
Dominance in the Rare Disease Market and Financial Outlook
Sanofi's Gaucher disease franchise maintains a strong presence in the global market, which is valued at approximately $1.8 billion. Cerdelga generated sales of €333 million in 2024 and has maintained solid quarterly results of approximately €80 million in 2025. The royalty rights to the original drug, owned by the University of Michigan, were sold to PDL BioPharma for $65.6 million, reflecting its high financial value. In the future, it is expected to continue to play a stable role as a cash cow, based on the expanded pediatric indication and a solid pricing strategy.
In the global $1.8 billion Gaucher disease treatment market, Cerdelga competes with enzyme replacement therapies (ERTs) such as Cerezyme and VPRIV, and has established itself as the only primary oral substrate reduction therapy (SRT). The continued EMA approval in Europe, along with the recommendation to expand the indication to include children aged 6 years and older, is expected to further drive the growth of Sanofi's Gaucher disease franchise by entering the new pediatric segment. In particular, the precedent of the University of Michigan's Cerdelga royalty rights being traded to PDL BioPharma for $65.6 million demonstrates the commercial viability and predictable cash flow value of this asset. In the long term, there is a potential threat from gene therapies (such as FLT201), but the expanded pediatric indication for Cerdelga will play a critical role in defending Sanofi's dominant market position in the Gaucher disease market in the medium term.
Source: EMA (ema)